Indeed, Berndtsson et al. [69] suggested that whereas the TCS response observed in p53-WT human cancer cells exposed to low biologically/clinically-relevant concentrations of cisplatin may be triggered primarily by DNA damage, the apoptosis seen after high/supralethal concentrations of the drug (Figure 3 and Figure 4) is perhaps an “off-target” response to cytoplasmic damage/ROS generation, possibly triggered by cisplatin-protein adducts. The gene discussed is TP53; the disease is cancer.